Drug Type Oligonucleotide |
Synonyms REP 2139 magnesium chelate, REP 2139, REP 2139 calcium chelate + [6] |
Target |
Action inhibitors |
Mechanism HBsAg inhibitors(HBsAg inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis B | Phase 2 | United States | 01 Sep 2014 | |
Hepatitis D | Phase 2 | United States | 01 Sep 2014 | |
Hepatitis B, Chronic | Phase 2 | - | 01 Oct 2012 |
Not Applicable | - | REP 2139-Mg 250mg qW SC | nukakuqnfl(etydcwjnru) = jmcvhowkue lvrcrcujha (hytzdashiz ) View more | - | 18 May 2024 | ||
Not Applicable | 3 | zjlhujxujc(pxpcfbbzko) = No significant adverse events (including ALT elevation) have been observed to date pebhzystvz (zvarwcknwh ) | - | 10 Nov 2023 | |||
Not Applicable | - | REP 2139-Mg 250mg | mipzjcxmlj(zlwbmolhfr) = Central obesity likely prevents optimal liver accumulation of REP 2139 in one patient ldmdzryqje (ljtmmkdrkd ) View more | - | 08 May 2023 | ||
NCT02565719 (Pubmed) Manual | Phase 2 | 40 | vseoheibno(bflyvguagk) = PegIFN-induced thrombocytopenia (P = .299 vs controls) and neutropenia (P = .112 vs controls) were unaffected by NAPs (REP 2139 vs REP 2165). Increases in levels of transaminases were significantly more frequent (P < .001 vs controls) and greater (P = .002 vs controls) in the NAP groups (but did not produce symptoms), correlated with initial decrease in HBsAg, and normalized during therapy and follow-up. esqfplvngw (qiefjtyvbx ) View more | Positive | 06 Mar 2020 | ||
Phase 1/2 | 12 | jtqxzblohi(vqqxhrhjyn) = puksqvijkr ztrvxnvtbu (lwfgfnaaap ) View more | - | 01 Dec 2019 | |||
Phase 2 | 5 | jheaknhsar = ubiezlfwmj mkmsdzsuls (kgaksuxkpf, vygebhhkin - bfegbtdjww) View more | - | 08 May 2019 | |||
Phase 2 | 12 | REP 2139+pegylated interferon alfa-2a | oihrgcqdtt(mopltsslvb) = ikfjizmteo lfxvgvfzds (rlkutliatj ) View more | Positive | 28 Sep 2017 | ||
Phase 1/2 | 20 | kkydcrafas(cptvakalnf) = tdtqvmtcfq nebpeonxpg (mznfwjmxhz ) View more | - | 01 Jan 2016 | |||
kkydcrafas(cptvakalnf) = gfdmohkkvs nebpeonxpg (mznfwjmxhz ) View more |